Becton, Dickinson and Company's Stock Analysis

Becton Dickinson Resumes Shipment of ChloraPrep and PurPrep

Becton Dickinson and Company has resumed the shipment of its ChloraPrep™ product in the U.S. after conducting additional final release testing. The company had previously placed both ChloraPrep™ and PurPrep™ on ship hold due to a Warning Letter received from the FDA regarding its El Paso manufacturing facility. Following the completion of assessments, all testing results have been acceptable, and there have been no reported patient safety issues.

The ship hold was implemented to ensure patient care continuity while addressing the concerns raised by the FDA. Investors should note that the situation surrounding the El Paso manufacturing facility and the associated Warning Letter could impact future operations and compliance. For further details regarding the El Paso Warning Letter and related risks, investors are advised to refer to the company's Quarterly Report on Form 10-Q for the period ended March 31, 2026.

May 29, 2026 08:39:28

Becton Dickinson Issues €600 Million in Notes Due 2033

On May 20, 2026, Becton Dickinson Euro Finance S.à r.l., a wholly-owned subsidiary of Becton, Dickinson and Company, issued €600 million of 3.855% Notes due in 2033 in a public offering. These notes are fully guaranteed by Becton, Dickinson and Company and can be redeemed prior to maturity under certain conditions. The proceeds from this offering will primarily be used to repay existing notes due June 4, 2026, and cover related expenses, with any remaining funds allocated for general corporate purposes.

The indenture governing the notes includes provisions for potential redemption based on tax law changes and a requirement to repurchase notes in the event of a change of control. Events of default include failure to make interest or principal payments, and the indenture imposes restrictions on certain corporate actions, such as mergers or asset sales. This issuance and its terms may influence Becton Dickinson's financial stability and liquidity, which are pertinent factors for investors.

May 20, 2026 17:05:06

Becton Dickinson Announces €600 Million Notes Offering

Becton Dickinson and Company, along with its subsidiary Becton Dickinson Euro Finance S.à r.l., has entered into an underwriting agreement for the sale of €600 million in 3.855% Notes due 2033. The offering is being underwritten by Barclays Bank PLC, BNP PARIBAS, Goldman Sachs & Co. LLC, and Morgan Stanley & Co. International plc, among others.

The net proceeds from this offering will be used to repay the outstanding principal of the 1.208% Euro Notes due June 4, 2026, along with any accrued interest, fees, and expenses. The completion of the offering is expected around May 20, 2026, pending customary closing conditions.

May 12, 2026 16:30:54

Becton Dickinson Reports Q2 2026 Financial Results and Guidance

Becton, Dickinson and Company announced its financial results for the second fiscal quarter ending March 31, 2026, reporting revenue of $4.7 billion, which reflects a 5.2% increase. The company reported a GAAP diluted EPS of $(0.13) and an adjusted diluted EPS of $2.90. In addition, BD executed a $2.0 billion accelerated share repurchase program and retired $2.1 billion of debt during the quarter. The company reaffirmed its revenue growth guidance while raising its full-year adjusted diluted EPS guidance.

Recent business highlights include the launch of several new products and partnerships aimed at enhancing patient care and safety. BD reported significant growth across its segments, with over 90% of the business achieving mid-single-digit growth. The company also received multiple regulatory approvals for new medical devices, further advancing its product portfolio. Following the spin-off of its former Biosciences and Diagnostic Solutions business, BD has reorganized into four distinct segments to streamline operations.

May 07, 2026 06:30:49

Becton Dickinson Amends By-Laws Affecting Corporate Governance

Becton, Dickinson and Company announced on April 28, 2026, that its Board of Directors approved amendments to the Company's By-laws. These amendments specifically update the advance notice provision regarding the timeline for determining contested elections, along with making several technical, conforming, and clarifying revisions.

The full text of the amended By-laws has been filed as an exhibit and is available for review. This update may influence corporate governance practices, which could have implications for shareholder engagement and decision-making processes.

Apr 29, 2026 16:16:44

Becton Dickinson Announces Retirement of Executive Vice President

Becton, Dickinson and Company (BD) has announced that Richard E. Byrd, the Executive Vice President and President of the Interventional segment, will retire after nearly 25 years with the company. Byrd, who has held various leadership roles since joining BD in 2004, will continue in his position until June 2026, with plans to name a successor before his departure.

During his tenure, Byrd contributed significantly to BD's growth and operational improvements, particularly in Vascular Access Management and during the COVID-19 pandemic. The company emphasized Byrd's impact on their portfolio and operational rigor, highlighting his leadership in advancing BD's role in global healthcare. BD is recognized as one of the largest medical technology companies, focusing on innovation to enhance patient care and clinical efficiency.

Apr 09, 2026 16:18:47

Becton Dickinson Completes Spin-Off and Provides Financial Updates

Becton Dickinson and Company announced the completion of its spin-off of the Biosciences and Diagnostic Solutions business, which has been combined with Waters Corporation, as of February 9, 2026. To aid investors, the company provided recast historical financial information that reflects the former business as discontinued operations, offering a clearer view of its ongoing operations. This information includes non-GAAP financial measures that adjust for various costs associated with acquisitions, restructuring, and regulatory compliance, which may affect year-over-year comparability.

The non-GAAP financial measures presented by Becton Dickinson include adjustments for purchase accounting, integration costs, and regulatory compliance expenses related to new European Union medical device regulations. These adjustments are aimed at providing a more accurate representation of the company's operational performance. However, the company cautions that these non-GAAP measures should not replace traditional GAAP results and that investors should review the complete financial statements for a comprehensive understanding of the company's financial health.

Apr 02, 2026 16:18:23

Becton Dickinson Announces Tender Offer Results and Pricing

Becton Dickinson and Company has announced the early tender results for its tender offers to purchase up to $2 billion of certain outstanding debt securities. The company has increased its Aggregate Offer Cap from $1.6 billion to $2 billion and amended the Offer SubCap for the 4.685% Senior Notes. As of the early tender date, a total of $36.5 million of the 6.700% Senior Notes, $32.8 million of the 7.000% Senior Debentures, and various amounts from other series of securities were tendered, exceeding the Aggregate Offer Cap, leading to a prorated acceptance for the 3.794% Senior Notes.

The company will make payments for the accepted securities on February 27, 2026, and holders of the validly tendered securities will also receive accrued interest. The tender offers are fully subscribed, and no additional purchases are expected after the early tender date. Investors are encouraged to refer to the Offer to Purchase for complete terms and conditions related to the tender offers.

Feb 25, 2026 16:25:34

Becton Dickinson Initiates $1.6 Billion Debt Tender Offers

Becton Dickinson and Company has announced the commencement of tender offers to purchase up to $1.6 billion in cash for various series of its outstanding debt securities. The offers include senior notes and debentures with different interest rates and maturity dates, and are subject to specific acceptance levels and purchase caps. The tender offers will expire on March 11, 2026, with an early tender date of February 24, 2026, for those wishing to receive additional consideration.

Investors interested in participating must validly tender their securities by the specified dates to receive the total consideration, which includes accrued interest. The company reserves the right to adjust the aggregate purchase price and other terms as necessary. Citigroup Global Markets Inc. and Wells Fargo Securities, LLC are the lead dealer managers for these offers, with further details available in the Offer to Purchase document provided to holders of the securities.

Feb 10, 2026 16:16:23

Becton Dickinson Completes Spin-Off and Merger with Waters Corporation

Becton Dickinson and Company has successfully completed the spin-off of its Biosciences and Diagnostic Solutions business, which has been combined with Waters Corporation. As part of the transaction, BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD common stock held as of February 5, 2026. BD also received a cash distribution of $4 billion from SpinCo, which it plans to allocate for share repurchases and debt repayment.

Following the merger, BD shareholders now own 39.2% of the outstanding shares of the combined company, valuing the spun-off business at $18.8 billion based on recent stock prices. Additionally, Claire M. Fraser has transitioned from the BD Board of Directors to join the Waters Board. The completion of these transactions is seen as a significant step in BD's strategic plan to focus on its core medical technology business.

Feb 09, 2026 16:18:11